Best Practice & Research Clinical Haematology最新文献_第4页

A reflection on Arnold Caplan, the father of MSC 对MSC之父阿诺德·卡普兰的反思

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 Epub Date: 2025-02-06 DOI: 10.1016/j.beha.2025.101597

James M. Anderson

引用次数: 0

Analyte heterogeneity analysis as a possible potency parameter for MSC 分析物异质性分析作为MSC可能的效价参数

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 Epub Date: 2025-02-06 DOI: 10.1016/j.beha.2025.101596

David Kaplan , Eric Christian , Sarah Planchon Pope , Hillard M. Lazarus , Jeffrey A. Cohen

{"title":"Analyte heterogeneity analysis as a possible potency parameter for MSC","authors":"David Kaplan , Eric Christian , Sarah Planchon Pope , Hillard M. Lazarus , Jeffrey A. Cohen","doi":"10.1016/j.beha.2025.101596","DOIUrl":"10.1016/j.beha.2025.101596","url":null,"abstract":"<div><div>Mesenchymal stem/stromal cells (MSC) have been transplanted for therapeutic purposes with inconsistent results. MSC preparations are heterogeneous, and this person-to-person heterogeneity may account for the variable clinical outcomes. Additionally, the mechanisms of therapeutic action for MSC are unclear which confounds attempts to understand and identify factors that may account for variable clinical results. Here, we report our analysis of MSC preparations for the expression levels of molecules that have been hypothesized to mediate MSC function. Although most of the analytes assessed demonstrated little divergent expression, several molecules were found with enhanced heterogeneity both within individual MSC preparations and among MSC preparations from the sample of multiple sclerosis patients. The variable expression of these molecules may relate to the therapeutic heterogeneity of MSC. Additionally, we found a novel set of molecules that were highly intercorrelated in MSC. The tight association of this group of molecules may represent an invariant molecular organization that is integral to MSC activity. The precise analysis of molecular expression levels in MSC has the potential to answer concerns about variable therapeutic effects of MSC transplantation as well as to understand the mechanism of clinical effects.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101596"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokine therapy of acute radiation syndrome 急性放射综合征的细胞因子治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 Epub Date: 2025-02-26 DOI: 10.1016/j.beha.2025.101599

Hillard M. Lazarus , Robert Peter Gale

引用次数: 0

Bispecific antibody therapy for lymphoma 淋巴瘤的双特异性抗体治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 Epub Date: 2025-02-15 DOI: 10.1016/j.beha.2025.101598

Genevieve M. Gerhard, Gottfried von Keudell

引用次数: 0

CARs for lymphoma car - t治疗淋巴瘤

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 Epub Date: 2025-02-27 DOI: 10.1016/j.beha.2025.101601

Ishan J. Tatake, Jon E. Arnason

引用次数: 0

Cytomegalovirus in haematopoietic cell transplantation - The troll is still there 造血细胞移植中的巨细胞病毒--巨怪依然存在

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.1016/j.beha.2024.101565

Sebastian Voigt

引用次数: 0

Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy 干扰 KIR 和 NKG2A 免疫检查点轴释放 NK 细胞免疫疗法

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1016/j.beha.2024.101568

Nicky A. Beelen , Vera T.C. Valckx , Gerard M.J. Bos , Lotte Wieten

{"title":"Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy","authors":"Nicky A. Beelen , Vera T.C. Valckx , Gerard M.J. Bos , Lotte Wieten","doi":"10.1016/j.beha.2024.101568","DOIUrl":"10.1016/j.beha.2024.101568","url":null,"abstract":"<div><p>Due to their intrinsic ability to eliminate malignant cells, natural killer (NK) cells emerge as a promising immunotherapy for cancer. While clinical studies have affirmed the safety of NK cell infusions and combination therapies have demonstrated encouraging outcomes in hematological malignancies, the efficacy of NK cell immunotherapeutic interventions remains heterogeneous across patient cohorts. Moreover, the implementation of NK cell immunotherapy in solid tumors presents notable challenges. Interfering with key NK cell inhibitory signaling pathways by targeting inhibitory killer cell immunoglobulin-like receptors (KIRs) and CD94/NK group 2 member A (NKG2A), holds promise for unleashing the full potential of NK cell-based immunotherapy. In this review, we provide an overview of the current approaches for interfering with inhibitory KIR and NKG2A signaling, exploring a selection of the multitude of combination strategies available. We discuss the significance of maintaining the delicate balance between achieving optimal suppression of NK cell inhibition and ensuring effective activation of anti-tumor effector function, while preserving the favorable safety profiles. The consideration of strategies to modulate inhibitory signaling pathways associated with KIR and NKG2A presents promising avenues for enhancing the efficacy of NK cell immunotherapy.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101568"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease 破译主要组织相容性复合体、肠道微生物组和代谢物在急性移植物抗宿主病发病机制中的作用

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.1016/j.beha.2024.101567

Valentin Wenger , Robert Zeiser

{"title":"Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease","authors":"Valentin Wenger , Robert Zeiser","doi":"10.1016/j.beha.2024.101567","DOIUrl":"10.1016/j.beha.2024.101567","url":null,"abstract":"<div><p>Allogeneic hematologic stem cell transplantation is a cornerstone in modern hematological treatment, yet its efficacy is compromised by acute Graft-versus-Host Disease. In acute Graft-versus-Host Disease, conditioning regimen induced epithelial damage leads to release of damage and pathogen associated molecular patters which in turns triggers activation of alloreactive donor T cells, ultimately resulting in destruction of healthy tissue. Advances in major histocompatibility complex typing and preclinical studies using tissue specific major histocompatibility complex deletion have illuminated the contributions of both, hematopoietic and non-hematopoietic cells to acute Graft-versus-Host Disease pathophysiology. Concurrently, high-throughput sequencing techniques have enabled researchers to recognize the significant impact of the intestinal microbiome and newly discovered metabolites in the pathophysiology of acute Graft-versus-Host Disease. In this review, we discuss the implications of major histocompatibility complex expression on hematopoietic and non-hematopoietic cells, the effect on the intestinal microbiome and the metabolic alterations that contribute to acute Graft-versus-Host Disease. By combining these findings, we hope to untangle the complexity of acute Graft-versus-Host Disease, ultimately paving the way for the development of novel and more effective treatmen options in patients.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101567"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000331/pdfft?md5=c71c173468158c3486a91814049fbdbf&pid=1-s2.0-S1521692624000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation 供体特异性 HLA 抗体与造血细胞移植的相关性

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1016/j.beha.2024.101576

Thuong Hien Tran , Andreas Heinold , Magdalena Spackova , Lien Pham , Matthias Stelljes , Peter Dreger

{"title":"Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation","authors":"Thuong Hien Tran , Andreas Heinold , Magdalena Spackova , Lien Pham , Matthias Stelljes , Peter Dreger","doi":"10.1016/j.beha.2024.101576","DOIUrl":"10.1016/j.beha.2024.101576","url":null,"abstract":"<div><p>Advances in hematopoietic cell transplantation have expanded the use of alternative donors such as haploidentical family donors or mismatched unrelated donors. However, donor-specific HLA antibodies (DSA) have been recognized as a significant risk factor of primary graft failure after HLA incompatible transplantation. Therefore, screening for HLA antibodies and taking DSA into consideration in the process of donor search play an increasingly important role in donor selection. If an HLA compatible donor is not available, desensitization may enable a successful transplantation. In this review, we describe the currently most widely used methods for HLA antibody detections including their pitfalls. In addition, we summarize the results of the studies on the impact of preformed DSA on transplant outcomes and their treatment options. Many more and larger studies are needed to clarify laboratory issues as well as immunological and clinical aspects in the management of DSA.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101576"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000422/pdfft?md5=b49527640064925941dcb5a8e246207a&pid=1-s2.0-S1521692624000422-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation 从克隆到免疫肽组：造血细胞移植中允许的 HLA-DP 错配特征研究的新进展

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1016/j.beha.2024.101575

Esteban Arrieta-Bolaños

{"title":"From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation","authors":"Esteban Arrieta-Bolaños","doi":"10.1016/j.beha.2024.101575","DOIUrl":"10.1016/j.beha.2024.101575","url":null,"abstract":"<div><p>Mismatching at the HLA-DPB1 locus occurs frequently in hematopoietic cell transplantation with unrelated donors. Despite this, HLA-DPB1 allelic mismatches have traditionally not been considered in patient-donor matching. A T-cell epitope (TCE) model for the functional assessment of permissive mismatches at this locus has nevertheless been adopted in clinical practice. While initially based on a hierarchical immunogenicity elucidated from allorecognition by T-cell clones isolated from a patient, newer developments in the understanding of this model's biological basis, including a central role for immunopeptidome divergence between mismatched allotypes, have prompted changes in the assignment of permissiveness, providing the opportunity for a more granular evaluation of graft-<em>versus</em>-host disease and relapse risks according to the nature and directionality of permissive mismatches. How these advances impact the assessment of permissiveness at HLA-DPB1 and potentially the intelligent selection of donors according to the main clinical goal for different patients is the subject of the present review.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101575"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000410/pdfft?md5=eccbdb3e12a17ab67dc0a72288f21c09&pid=1-s2.0-S1521692624000410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0